Clay Thorp Executive Chairman
Since 1995, Clay has co-founded seven companies in the life science arena including PhaseBio Pharmaceuticals. He also co-founded Hatteras Venture Partners in 2000, and has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $350 million across five funds. Clay was co-founder, CEO and Chairman of Synthematix, Inc., a chemistry informatics company acquired in April 2005 by Symyx Technologies (SMMX). He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Clay currently serves as Chairman of GeneCentric Diagnostics and is on the boards of Clearside Biomedical, Curoverse, Lysosomal Therapeutics, and Orig3n. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.
Ashutosh Chilkoti, PhD
Ashutosh is a co-founder of PhaseBio, a professor in the biomedical engineering department at Duke University. His research in biomolecular materials and surface science emphasizes the development of applications that span the range from bioseparations, biosensors, patterned biomaterials and targeted drug delivery. Ashutosh invented PhaseBio’s drug delivery technology and serves as the company’s scientific advisor in protein purification and drug delivery.
Nancy Hutson, PhD
Nancy has more than 30 years of experience in the pharmaceutical industry. She retired from Pfizer Inc. in 2006 after spending 25 years in research and leadership positions, most recently serving as Senior Vice President of Global Research & Development and Director of Pfizer’s pharmaceutical research and development site Groton / New London Laboratories. Nancy currently serves on the boards of directors for BioCryst Pharmaceuticals, Inc. and Endo International plc, and on the scientific advisory board of Hatteras Venture Partners. She received a Ph.D. in physiology and biochemistry from Vanderbilt University and a B.A. in general biology from Illinois Wesleyan University.
Justin Klein, MD, JD
Justin joined New Enterprise Associates (NEA) in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of Advanced Cardiac Therapeutics, Cartiva, FIRE1, Intact Vascular, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics, VertiFlex, and VytronUS. Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed’s Business Development Committee. Prior to NEA, Justin worked for the Duke University Health System, reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations. Justin has an AB in Economics and a BS in Biological Anthropology and Anatomy from Duke University, an MD from the Duke University School of Medicine and a JD from Harvard Law School.
Han Lee, PhD
Han Lee is currently a Senior Director within AstraZeneca’s Corporate Development and Ventures group, having responsibility for mergers and acquisitions, transformative deals, and strategic equity investments. Prior to AstraZeneca, Han was an integral part of two biotech start-ups that both had successful exits and was a part of entrepreneurial teams that raised over $100 million. Han received his BA in Genetics and minor in Chemistry from the University of California, Berkeley. He received his PhD in Genetics and his MBA from Yale University.
Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management. He is chief executive officer of PhaseBio, and previously served as the company’s chief business officer. Prior to PhaseBio, Jonathan served as vice president, business development for Amylin Pharmaceuticals from 2007 until its sale to Bristol-Myers Squibb in 2012. Jonathan was co-founder and vice president, commercial and business development of Corus Pharma, Inc. until its acquisition by Gilead Sciences in 2006. Earlier in his career, he led the business development efforts for PathoGenesis Corporation, culminating in the company’s acquisition by Chiron Corporation in 2000. Jonathan has held positions in sales and marketing at Bristol-Myers Squibb, Wyeth / Lederle International and Syntex Laboratories. Jonathan holds a BS in Mechanical Engineering from UC Berkeley and an MBA from Carnegie Mellon University Tepper School of Business.
Bibhash Mukhopadhyay, PhD
Bibhash is a Principal at NEA, where he focuses on investing in emerging therapeutic and device companies, assisting them grow and create value. Previously, he was Associate Director of Business Development at AstraZeneca / MedImmune, and held multiple business development positions at Johnson & Johnson. Bibhash has a PhD in Biomedical Sciences from Baylor College of Medicine, an MS in Neuroscience from Georg-August-Universität, Göttingen, and a BS in Biochemistry and Molecular Biology from the All India Institute of Medical Sciences, New Delhi.
Marian Nakada, PhD
Marian is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC Inc., the corporate venture arm of Johnson & Johnson. She is based in the Boston Innovation Center and focuses on investments in East Coast companies in areas of strategic interest to Janssen R&D. Marian previously held roles at Centocor R&D, Janssen R&D, and Janssen Business Development. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania. Marian was the JJDC investor for CoStim Pharmaceuticals, Vedanta Biosciences, Rodin Therapeutics, and Padlock Therapeutics and currently also sits on the Boards of Navitor Pharmaceuticals and the New England Venture Capital Association.
Linda has more than 35 years of experience working with companies across healthcare and life sciences. At present, she is a General Partner at Fletcher Spaght Ventures and Fletcher Spaght, Inc., a Boston-based consultancy focused on growth strategies for healthcare and IT clients. Prior to Fletcher Spaght, she held positions at the Sony Corporation of America and Bain & Company. Linda currently serves on the boards of directors at Juventas Therapeutics and HistoSonics. She earned an SB in Electrical Engineering and Computer Science and an SB in Humanities and Science (Physics) from the Massachusetts Institute of Technology (MIT), and an SM in Management (Finance) from the MIT Sloan School of Management.